Gsa Capital Partners LLP Zentalis Pharmaceuticals, Inc. Transaction History
Gsa Capital Partners LLP
- $1.35 Billion
- Q4 2024
A detailed history of Gsa Capital Partners LLP transactions in Zentalis Pharmaceuticals, Inc. stock. As of the latest transaction made, Gsa Capital Partners LLP holds 144,170 shares of ZNTL stock, worth $350,333. This represents 0.03% of its overall portfolio holdings.
Number of Shares
144,170
Previous 608,585
76.31%
Holding current value
$350,333
Previous $2.24 Million
80.49%
% of portfolio
0.03%
Previous 0.17%
Shares
8 transactions
Others Institutions Holding ZNTL
# of Institutions
142Shares Held
68.4MCall Options Held
48.5KPut Options Held
89.6K-
Matrix Capital Management Company, LP Waltham, MA14MShares$33.9 Million2.05% of portfolio
-
Eventide Asset Management, LLC Boston, MA8.55MShares$20.8 Million0.55% of portfolio
-
Black Rock Inc. New York, NY4.82MShares$11.7 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.27MShares$7.95 Million0.0% of portfolio
-
Decheng Capital LLC Menlo Park, CA3.11MShares$7.55 Million2.71% of portfolio
About Zentalis Pharmaceuticals, Inc.
- Ticker ZNTL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 56,983,600
- Market Cap $138M
- Description
- Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidate includes the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trial for the treatment of advanced solid ...